Results 171 to 180 of about 3,090 (189)
Some of the next articles are maybe not open access.

Activity of PU-H71, a novel HSP90 inhibitor, and bortezomib in Ewing sarcoma preclinical models.

Journal of Clinical Oncology, 2013
3101 Background: Heat shock protein (HSP) 90 regulates the disposition and activity of a large number of deregulated proteins in Ewing sarcoma. We have shown pre-clinical efficacy of PU-H71, a novel HSP90 inhibitor developed at MSKCC, in Ewing sarcoma. Unfolded proteins as a result of HSP90 inhibition are degraded via the ubiquitin-proteasome pathway
Srikanth R. Ambati   +8 more
openaire   +1 more source

Mechanism of the antimyeloma activity of PU-H71, a novel purine scaffold HSP90 inhibitor.

Journal of Clinical Oncology, 2010
8141 Background: PU-H71, a novel purine scaffold HSP90 inhibitor, has demonstrated anti-tumor activity in triple-negative breast cancer and Bcl6 dependent B-cell lymphoma preclinical models.
S. Z. Usmani   +3 more
openaire   +1 more source

Antitumor Efficacy of the Purine-Scaffold Hsp90 Inhibitor PU-H71 in Diffuse Large-B Cell Lymphoma

Blood, 2008
Abstract Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma. Although many DLBCLs are responsive to CD20 antibody/chemotherapy regimens, a significant proportion of patients will still die of their disease. It is possible that targeting important lymphomagenic pathways could improve the potency and reduce the ...
Gabriela Chiosis   +4 more
openaire   +1 more source

Abstract 7326: PU-H71 alters metabolism to suppress growth in pancreatic cancer

Cancer Research
Abstract Pancreatic ductal adenocarcinoma (PDAC) is a deadly cancer with limited therapeutic options. Oncogenic KRAS signaling, mainly via the mitogen-activated protein kinase (MAPK) pathway, is the key driver of PDAC. To sustain its growth and resist therapy, PDAC tumors continuously reprogram their metabolic activities.
Chiamaka J. Ezeh   +3 more
openaire   +1 more source

Abstract P6-20-03: Tumor epichaperome expression using 124I PU-H71 PET (PU-PET) as a biomarker of response for PU-H71 plus nab-paclitaxel in HER2 negative (HER2-) metastatic breast cancer (MBC)

Cancer Research, 2019
Abstract Background: The epichaperome is a new cancer target required for tumor survival (Joshi et al. Nature Reviews Cancer 2018). PU-H71 is a synthetic, purine scaffold epichaperome inhibitor that binds to the ATP-binding site of HSP90 specifically when HSP90 is integrated into the epichaperome (Rodina et al. Nature 2016).
K Jhaveri   +16 more
openaire   +1 more source

A facile and efficient synthesis of d6‐labeled PU‐H71, a purine‐scaffold Hsp90 inhibitor

Journal of Labelled Compounds and Radiopharmaceuticals, 2009
AbstractPU‐H71 is a purine‐scaffold Hsp90 inhibitor currently undergoing late stage preclinical evaluation for the treatment of cancer. In this investigation, we present a simple method for the synthesis of d6‐labeled PU‐H71 for use as an internal standard to accurately quantitate the drug in biological matrices based on an LC‐MS‐MS method.
Tony Taldone   +3 more
openaire   +1 more source

MPEC 2026-H71 : 2026 HX1

The Minor Planet Electronic Circulars contain information on unusual minor planets, routine data on comets and natural satellites, and occasional editorial announcements. They are published on behalf of Division F of the International Astronomical Union by the Minor Planet Center, Smithsonian Astrophysical Observatory, Cambridge, MA 02138, U.S.A.
openaire   +1 more source

EFFECT OF SOLUBLE POLYLACTIC ACID IN COMBINATION WITH GAMMA RADIATION ON GROUND BEEF INOCULATED WITH E. COLI O157:H71

Foodservice Research International, 1999
Ground beef was inoculated with E. coli O157:H7 and treated with gamma radiation with and without the incorporation of a 2% soluble polylactic acid solution (SPLA) and stored at 4C for up to 7 days. Frozen samples received an average maximum dose of 125 krads, at an average dose rate of 17.1 krads/h.
TOM WILSON   +4 more
openaire   +1 more source

MPEC 2024-H71 : 2024 HK1

The Minor Planet Electronic Circulars contain information on unusual minor planets, routine data on comets and natural satellites, and occasional editorial announcements. They are published on behalf of Division F of the International Astronomical Union by the Minor Planet Center, Smithsonian Astrophysical Observatory, Cambridge, MA 02138, U.S.A.
openaire   +1 more source

MPEC 2025-H71 : 2025 HB1

The Minor Planet Electronic Circulars contain information on unusual minor planets, routine data on comets and natural satellites, and occasional editorial announcements. They are published on behalf of Division F of the International Astronomical Union by the Minor Planet Center, Smithsonian Astrophysical Observatory, Cambridge, MA 02138, U.S.A.
openaire   +1 more source

Home - About - Disclaimer - Privacy